Clinical Trial Update: Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Mecapegfilgrastim to prevent neutropenia induced by dalpiciclib in metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Mecapegfilgrastim

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING